Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $115.79 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vaxart Inc had its IPO on 2018-02-12 under the ticker symbol VXRT.
The company operates in the Healthcare sector and Biotechnology industry. Vaxart Inc has a staff strength of 164 employees.
Shares of Vaxart Inc opened at $0.81 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $0.75 - $0.83, and closed at $0.76.
This is a -5.47% slip from the previous day's closing price.
A total volume of 981,871 shares were traded at the close of the day’s session.
In the last one week, shares of Vaxart Inc have increased by +2.33%.
Vaxart Inc's Key Ratios
Vaxart Inc has a market cap of $115.79 million, indicating a price to book ratio of 1.1053 and a price to sales ratio of 916.2665.
In the last 12-months Vaxart Inc’s revenue was $107000 with a gross profit of $-9076000 and an EBITDA of $-104528000. The EBITDA ratio measures Vaxart Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vaxart Inc’s operating margin was -103114.95% while its return on assets stood at -36.78% with a return of equity of -72.29%.
In Q4, Vaxart Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 70.3%.
Vaxart Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.83 per share while it has a forward price to earnings multiple of 42.735 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vaxart Inc’s profitability.
Vaxart Inc stock is trading at a EV to sales ratio of 267.8463 and a EV to EBITDA ratio of -0.4342. Its price to sales ratio in the trailing 12-months stood at 916.2665.
Vaxart Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $153.85 million
- Total Liabilities
- $17.92 million
- Operating Cash Flow
- $15.80 million
- Capital Expenditure
- $3.90 million
- Dividend Payout Ratio
Vaxart Inc ended 2023 with $153.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $153.85 million while shareholder equity stood at $110.60 million.
Vaxart Inc ended 2023 with $0 in deferred long-term liabilities, $17.92 million in other current liabilities, 13000.00 in common stock, $-327109000.00 in retained earnings and $4.51 million in goodwill. Its cash balance stood at $44.01 million and cash and short-term investments were $93.72 million. The company’s total short-term debt was $2,228,000 while long-term debt stood at $0.
Vaxart Inc’s total current assets stands at $99.45 million while long-term investments were $0.00 and short-term investments were $49.70 million. Its net receivables were $20000.00 compared to accounts payable of $5.51 million and inventory worth $0.
In 2023, Vaxart Inc's operating cash flow was $15.80 million while its capital expenditure stood at $3.90 million.
Comparatively, Vaxart Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vaxart Inc stock is currently trading at $0.76 per share. It touched a 52-week high of $5.32 and a 52-week low of $5.32. Analysts tracking the stock have a 12-month average target price of $6.13.
Its 50-day moving average was $0.9 and 200-day moving average was $2.03 The short ratio stood at 14.8 indicating a short percent outstanding of 0%.
Around 169.4% of the company’s stock are held by insiders while 3322.7% are held by institutions.
Frequently Asked Questions About Vaxart Inc
Similar Industry Stocks (Biotechnology)
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.